Chronic Lymphocytic Leukemia
Conditions
Keywords
Chronic Lymphocytic Leukemia, untreated, minimally treated, fludarabine, rituximab, lenalidomide
Brief summary
This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and rituximab, using a schedule similar to that examined by investigators at MD Anderson (J Clin Oncol 23(18):4079-88, 2005). Given that the optimal dose and schedule is not currently known, this trial will perform a phase I component followed by a phase II examination to further explore this regimen's activity.
Detailed description
While progress has been made in treating CLL patients over the last decade, a cure remains elusive for many patients treated with standard therapies. The combination of fludarabine, a purine analog, and rituximab, a monoclonal antibody, is an effective and frequently used therapy for CLL. However, this drug combination is associated with increased toxicity. Lenalidomide has been shown to be less toxic and has been used to treat hematologic malignancies including CLL. We propose this Phase I/Phase II study to examine the combination of lenalidomide with a rituximab/fludarabine backbone.
Interventions
DRUGlenalidomide
2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
DRUGRituximab
375 mg/m2 Cycle 1 (split over Day 1 & Day 2); 500 mg/m2 Day 1 of Cycles 2-6
DRUGFludarabine
25 mg/m2 on Days 1, 2, and 3
Sponsors
Celgene Corporation
Genentech, Inc.
SCRI Development Innovations, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Understand and voluntarily sign an informed consent form. * Able to adhere to the study visit schedule and other protocol requirements. * Age \>=18 years at the time of signing the informed consent form. * Patient must have histopathologically confirmed B-cell CLL * For Phase I only: Untreated or minimally treated patients (patients who have received only prior single agent rituximab) are eligible. For those patients who have had rituximab monotherapy, last dose must be greater than 90 days prior to beginning study treatment. * For Phase II only: Untreated B-cell CLL patients only. * Rai staging, will be employed. Patients must have Rai stage III/IV disease (irrespective of symptoms) OR symptomatic Rai stage 0-II disease, requiring therapy as defined by NCI 1996 guidelines. * Platelets must be \> 75,000/mm3 and absolute neutrophil count must be \> 1000/mm3 within 14 days of starting protocol treatment unless treating physicians deems the neutropenia is related to marrow involvement and then ANC \> 750/mm3 is allowed. * Serum creatinine \<=2.0 mg/dl obtained within 14 days of starting protocol treatment. Creatinine clearance as determined by the Cockroft-Gault formula, using ideal body weight, must be \> 30 mL/minute. * AST or ALT must be \< 3 x the upper limit of normal within 14 days of starting treatment. * ECOG performance of 0, 1 or 2. * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. * Disease free of prior malignancies for \>= 2 years (including carcinoma in situ of the cervix or breast) treated with curative intent and anticipated 5 year disease-free survival is greater than 90%. Any basal cell or squamous cell carcinoma of the skin treated with curative intent is permitted. * Able to take aspirin (325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use low molecular weight heparin).
Exclusion criteria
* Major surgery less than 28 days prior to study treatment. * Any prior use of lenalidomide or thalidomide. * Concurrent use of other anti-cancer therapies. * Pregnant or breast feeding females. (Lactating females may be considered if they agree not to breast feed while receiving study treatment and until 12 months following last dose of rituximab). * History of pulmonary embolus or deep vein thrombosis. * Clinically significant heart dysfunction, defined as New York Heart Association class III or IV, at the time of screening, or history of myocardial infarction or heart failure within 6 months preceding the first study treatment (cardiac ejection fraction must be \>= 50% within 8 weeks of beginning study treatment for any patient with a history of clinically significant heart dysfunction). * Known positive for HIV, hepatitis B surface Ag, hepatitis B core antibody, or hepatitis C. Mandatory testing is not required, but should be considered in patients deemed high risk or suspicious. * Active infection requiring oral or intravenous antibiotics at study entry. After infection resolves patient may be evaluated for enrollment. * Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura. * Richter's transformation. * CNS involvement. * Other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with interpretation of study results that in the judgment of the investigator would make the patient inappropriate for this study or that would prevent the patient from signing the informed consent form. * Use of any other biologic agent or disease-modifying anti-rheumatic drugs (DMARDS). * Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or any component of rituximab. * Evidence of laboratory TLS by Cairo-Bishop criteria (subjects may be enrolled upon correction of electrolyte abnormalities).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events as a Measure of Safety and Tolerability | 63 months | Recorded from first treatment until 30 days after last treatment and assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Complete Response Rate | At 12 weeks during treatment and 2 months post-treatment until disease progression, projected 8 months | An improvement in complete response to at least 60% following treatment, assessed using CT scans, clinical/lab examinations, and bone marrow aspirations, as defined by National Cancer Institute Working Group Response Criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | Every 3 months during treatment until disease progression and every 6 months thereafter, up to 5 years | Measured from first treatment to disease progression and assessed using Kaplan-Meier methods. |
| Overall Survival | Every 3 months until treatment discontinuation, expected average of 6 months and then every 6 months thereafter up to 5 years | Defined as the time from Day 1 of treatment administration to date of death from any cause, estimated using Kaplan-Meier methods. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 Rituximab 375 mg/m\^2 cycle 1 (split over Day 1 & Day 2), 500 mg/m\^2 Day 1 of cycles 2-6 Fludarabine 25 mg/m\^2 on days 1, 2 and 3 Lenalidomide 2.5 mg PO daily Days 8-28 all cycles 1-6 | 10 |
| Dose Level 2 Rituximab 375 mg/m\^2 cycle 1 (split over Day 1 & Day 2), 500 mg/m\^2 Day 1 of cycles 2-6 Fludarabine 25 mg/m\^2 on days 1, 2 and 3 Lenalidomide 2.5 mg PO daily Days 8-28 cycle 1, 5.0 mg PO days 8-28 cycles 2-6 | 54 |
| Total | 64 |
Baseline characteristics
| Characteristic | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Age, Continuous | 67 years | 63 years | 64 years |
| Gender Female | 2 Participants | 25 Participants | 27 Participants |
| Gender Male | 8 Participants | 29 Participants | 37 Participants |
| Region of Enrollment United States | 10 participants | 54 participants | 64 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 10 / 10 | 54 / 54 |
| serious Total, serious adverse events | 2 / 10 | 16 / 54 |
Outcome results
Primary
Complete Response Rate
An improvement in complete response to at least 60% following treatment, assessed using CT scans, clinical/lab examinations, and bone marrow aspirations, as defined by National Cancer Institute Working Group Response Criteria.
Time frame: At 12 weeks during treatment and 2 months post-treatment until disease progression, projected 8 months
Population: All patients deemed evaluable and evaluated for response
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 | Complete Response Rate | 4 participants |
| Dose Level 2 | Complete Response Rate | 9 participants |
Primary
Number of Adverse Events as a Measure of Safety and Tolerability
Recorded from first treatment until 30 days after last treatment and assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: 63 months
Population: All treated patients
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Back pain | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Thrombocytopenia | 8 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Headache | 1 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Anorexia | 4 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Chills | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Neutropenia | 7 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Insomnia | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Fever | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Vomiting | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Rash | 6 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Dysgeusia | 1 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Hyperhidrosis | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Abdominal Pain | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Leukopenia | 7 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Allergic Reaction | 4 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Arthralgia | 1 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Diarrhea | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Nausea | 7 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Cough | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Edema Limbs | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Dizziness | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Anemia | 8 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Dyspnea | 0 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Pruritus | 0 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Hypotension | 1 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Constipation | 3 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Myalgia | 2 participants |
| Dose Level 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Fatigue | 8 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Myalgia | 8 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Fatigue | 40 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Neutropenia | 41 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Anemia | 34 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Leukopenia | 34 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Thrombocytopenia | 30 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Rash | 27 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Nausea | 25 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Constipation | 15 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Anorexia | 12 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Fever | 13 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Hyperhidrosis | 13 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Arthralgia | 14 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Edema Limbs | 12 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Pruritus | 15 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Back pain | 11 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Headache | 13 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Chills | 11 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Insomnia | 11 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Vomiting | 11 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Dysgeusia | 11 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Abdominal Pain | 9 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Allergic Reaction | 7 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Diarrhea | 8 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Cough | 8 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Dizziness | 8 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Dyspnea | 10 participants |
| Dose Level 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Hypotension | 9 participants |
Secondary
Overall Survival
Defined as the time from Day 1 of treatment administration to date of death from any cause, estimated using Kaplan-Meier methods.
Time frame: Every 3 months until treatment discontinuation, expected average of 6 months and then every 6 months thereafter up to 5 years
Population: All treated patients, all dose levels
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Overall Survival | NA months |
Secondary
Progression-Free Survival
Measured from first treatment to disease progression and assessed using Kaplan-Meier methods.
Time frame: Every 3 months during treatment until disease progression and every 6 months thereafter, up to 5 years
Population: All treated patients, all dose levels
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Progression-Free Survival | 24.64 months |